Svenska  |  Site map  |  Contact

image

Principles for compensation of senior executives
Moberg Pharma shall offer a total compensation at market rate that enables for qualified senior executives to be recruited and retained. The compensation paid to the Chief Executive Officer and other senior executives may consist of basic salary, variable compensation, other benefits and pension benefits. The total compensation is based on the basic salary and must be proportionate to the executive’s responsibilities and authority. Variable compensation is capped at 50 per cent of each executive’s basic annual salary and is based on results achieved in relation to individually defined qualitative and quantitative targets as well as the company’s result in relation to goals set by the Board of Directors. Pensionable salary comprises only of basic salary. To the extent that Board members perform work for the company or any other group company, besides work in the Board of Directors, consultancy fee at market rate may be paid.

In case of termination, the notice period shall be at least three months if the senior executive takes the initiative and if the company takes the initiative between three and nine months. Severance is not paid. The Shareholders’ Meeting shall, when applicable, decide on all share and share-price related programs. Allotment shall be made in accordance with the resolution of the Shareholders’ Meeting. With the exception of the employee stock options allotted and accrued, and what is provided for under existing employment contracts as referred to above, senior executives are not entitled to any benefits after the termination of the employment/assignment.

The Board of Directors shall be entitled to deviate from the above mentioned principles for remuneration of senior executives if there are special reasons.

The compensation committee
The Board has a compensation committee, which prepares proposals on compensation issues. The committee consists of three Directors, Wenche Rolfsen (committee chairman), Mats Pettersson and Gustaf Lindewald. All are independent in relation to Moberg Pharma and the company’s senior executives. The committee’s principal tasks are to:

(i) prepare the Board’s decisions on issues relating to principles of compensation, compensation and other terms of employment for management,

(ii) monitor and evaluate ongoing and recently completed variable compensation schemes for management, and

(iii) monitor and evaluate the application of guidelines for compensation of senior executives that are legally subject to approval by the AGM and of applicable structures and levels of compensation in Moberg Pharma.

Decisions on compensation issues must, after drafting by the committee, be adopted by the Board as a whole.
Contact Investor relations: 

Magnus Persson, IR 
Phone: +46 733 55 26 01
Email: magnus.persson@mobergpharma.se  
 
Peter Wolpert, CEO
Phone +46 8 522 307 00
 

Moberg Pharma AB (publ)
Gustavslundsvägen 42, 5 tr, SE-167 51 Bromma, Sweden
Phone: +46 8 522 30 700
info@mobergpharma.se